Brought to you by 
Samsung tackles biopharma space in JV with Quintiles
30 Jan 2023
Executive Summary
To facilitate Samsung Electronics Co. Ltd.’s entry into the biopharma industry, the appliance and electronics maker has created a joint venture with Quintiles Transnational Corp. (clinical trials, marketing, and consulting services) that will provide contract manufacturing of biosimilars in South Korea.
Deal Industry
- Contract Research Organization-CRO
- Pharmaceuticals
- Services
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Samsung tackles biopharma space in JV with Quintiles
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice